Why the study?
Does decreased FAM13B expression increase atrial fibrillation susceptibility in preclinical models?
Does decreased FAM13B expression increase atrial fibrillation susceptibility in preclinical models?
Decreased FAM13B expression, linked to the AF risk variant rs17171731, increases susceptibility to atrial fibrillation by altering sodium current and calcium handling.
FAM13B may mediate AF arrhythmogenesis; leaves open therapeutic targeting pending human validation.
A specific genetic variant associated with atrial fibrillation risk, rs17171731, was identified as a regulatory variant responsible for controlling FAM13B expression. The atrial fibrillation risk allele decreases FAM13B expression, whose knockdown alters the expression of many genes in stem cell–derived cardiomyocytes, including SCN2B, and led to pro-arrhythmogenic changes in the late sodium current and Ca2+ cycling. Fam13b knockout mice had increased P-wave and QT interval duration and were more susceptible to pacing-induced arrhythmias vs control mice. FAM13B expression, its regulation, and downstream effects are potential targets for investigation of patient-specific therapeutics.
No takes yet. Share an insight, caveat, or question.
Tchou et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: